Mycobacterium xenopi is one of the most frequently isolated nontuberculous mycobacteria in Ontario, Canada. We reviewed the records of 28 human immunodeficiency virus (HIV) -infected patients from whom M. xenopi was isolated between 1982 and 1995. M. xenopi was recovered from respiratory specimens from 24 patients, most of whom had clinical and radiographic evidence of pulmonary disease. However, coexistent pulmonary infection due to other pathogens was found in 17 patients: Pneumocystis carinii (9 patients), cytomegalovirus (5), Haemophilus influenzae (2), Mycobacterium avium complex (2), Streptococcus pneumoniae (1), Staphylococcus aureus (1), Aspergillus species (1), and Histoplasma capsulatum (1). Three patients had bacteremia with M. xenopi, including two patients with pulmonary infection. Two of the bacteremic patients had chronic fever and a wasting syndrome. Twenty-one (75%) of the 28 patients were thought to be colonized, and seven patients (25%; of whom four had CD4 cell counts of £50/mm 3 ) were thought to have significant infection due to M. xenopi. Sixteen patients died, but in no case was death attributable to M. xenopi infection. In a region where M. xenopi is a relatively common mycobacterial isolate, the organism frequently colonizes HIV-infected patients. Significant disease occurs in those patients with more advanced HIV infection.
Mycobacterium xenopi was first described in 1959, when it infections including Pneumocystis carinii pneumonia, esophageal candidiasis, and recurrent orolabial herpes simplex virus was isolated from skin lesions of a toad (Xenopus laevis) [1] . It is a slow-growing, scotochromogenic nontuberculous mycoinfection. He was treated with zidovudine and trimethoprimsulfamethoxazole. In July 1991, he developed fever, night bacterium that is often considered to be a commensal or environmental contaminant. Although infrequently identified in the sweats, anorexia, and weight loss (Ç8 kg). These symptoms persisted, and in January 1992, blood cultures yielded M. xenUnited States [2] , the organism is reported to be endemic in parts of Europe [3 -5] and is also a relatively common mycoopi. A chest roentgenogram was unremarkable, and no other causes for his fever were identified. The CD4 cell count was bacterial isolate in southern Ontario, Canada [6, 7] . Respiratory tract infection has been well described, especially in individuals 14/mm 3 . The mycobacterial isolate was susceptible in vitro to streptowith chronic underlying pulmonary disease [6 -10] . The organism appears to be a rare cause of extrapulmonary or disseminmycin, clarithromycin, and ciprofloxacin; was intermediately susceptible to isoniazid; and was resistant to rifampin, ethamated infection [11 -13] . There have been occasional case reports of M. xenopi infection in immunocompromised patients, inbutol, and pyrazinamide. Treatment with isoniazid (300 mg/d), rifampin (600 mg/d), and ciprofloxacin (750 mg/d) was cluding those with HIV infection or AIDS [14 -18] . In this article, we describe a patient with M. xenopi bacteremia and started. Intermittent fever and weight loss persisted despite therapy, and blood cultures in September 1992 again yielded review the clinical features of 28 HIV-infected patients in Toronto from whom M. xenopi was isolated.
M. xenopi. The patient died 3 months later; permission for an autopsy was denied.
Thoracic Society [20] , were used to determine the clinical siggraphic changes included interstitial infiltrates, cavitation, atelectasis, pleural thickening, and lymphadenopathy. nificance of M. xenopi isolates from respiratory specimens. In addition, the organism was thought to be pathogenic if it was Three patients had bacteremia with M. xenopi. Two of these patients (patients 1 and 2) presented with a prolonged febrile isolated from a normally sterile site or from a nonsterile, nonrespiratory site in the presence of compatible clinical, radioillness with anorexia and weight loss. In two patients (patients 1 and 3), bacteremia was associated with pulmonary disease graphic, or histopathologic evidence of disease without another explanation. M. xenopi bacteremia was assumed to be indicaand recovery of the organism from respiratory tract specimens. These two patients also had coexistent P. carinii pneumonia. tive of disseminated disease.
M. xenopi was recovered from extrapulmonary sites in three other patients. One patient (patient 7) had chronic left inguinal lymphadenitis due to M. xenopi, which appeared to respond to Results antituberculous therapy. The organism was also isolated from a single stool specimen from a patient with chronic diarrhea A total of 28 HIV-infected patients (26 males and two females) from whom one or more isolates of M. xenopi had been (patient 27) and from a urine specimen from a 4-month-old boy with fever (patient 28). Subsequent cultures of specimens recovered were identified (table 1). The recovery of M. xenopi isolates occurred sporadically, without any apparent seasonal from both of these patients were negative for mycobacteria, and neither patient received antituberculous treatment. variation or temporal clustering. The mean age of the patients was 38 years (age range, 4 months to 61 years). Twenty patients M. xenopi was thought to be a clinically significant isolate in seven patients (25%) (table 1): three with bacteremia (pawere bisexual or homosexual men, three of whom were also intravenous drug users. tients 1 -3), three with pulmonary disease (patients 4 -6), and one with lymphadenitis (patient 7). M. xenopi was possibly The routes of acquisition of HIV infection in the other patients were heterosexual transmission (4 patients), injection pathogenic in three other patients (patients 8 -10) who did not meet the criteria of the American Thoracic Society [20] for drug use (2), transfusion of blood products (1), and perinatal transmission (1). Sixteen patients had had a prior AIDS-dedetermining the clinical significance of nontuberculous mycobacteria. These patients had compatible clinical and radiofining illness. Eight patients were receiving antiretroviral agents; none of the patients were receiving rifabutin as prographic findings and multiple respiratory tract isolates of M. xenopi, but other potential pathogens were also identified. phylaxis for Mycobacterium avium complex disease. Of the 24 patients for whom CD4 lymphocyte counts within 3 months of Of the six patients with clinically significant M. xenopi isolates (including two bacteremic patients) for whom CD4 cell counts the isolation of M. xenopi were available, 12 had CD4 cell counts of õ50/mm 3 , and seven had CD4 cell counts of bewere available, four had CD4 cell counts of £50/mm 3 , and five had CD4 cell counts of õ100/mm 3 . However, the mean tween 50 and 99/mm 3 . M. xenopi was recovered from lower respiratory tract speci-CD4 cell count for those patients with clinically significant isolates was not different from that for those patients in whom mens from 24 patients (86%): bronchoalveolar lavage fluid (16 patients), sputum (12) , and lung biopsy specimen (1). The M. xenopi was not thought to be clinically significant. Treatment with antituberculous medications was started for number of M. xenopi isolates ranged from one to six per patient. All of these patients had respiratory and/or constitutional sympfour of the patients meeting criteria for M. xenopi infection. One patient (patient 7) appeared to respond to therapy, and toms such as fever (69% of patients), cough (79%), dyspnea (58%), weight loss (46%), night sweats (29%), and hemoptysis two patients (patients 1 and 4) discontinued antituberculous treatment because of adverse reactions. Three other patients (17%). The duration of these symptoms ranged from 2 days to 20 months (median duration, 4 weeks). Coexistent pulmonary (patients 8, 11, and 13) also received antituberculous therapy, and one of these patients (patient 11) appeared to respond to infection due to one or more other potential pathogens was common, occurring in 17 patients. The coexistent pathogens treatment. A total of 16 patients died a median of 6 months (range, 3 days to 23 months) after the initial isolation of that were identified included P. carinii (9 patients), cytomegalovirus (5), M. avium complex (2), Haemophilus influenzae M. xenopi. In no case was death attributed to mycobacterial infection, although postmortem examinations were not done. (2), Streptococcus pneumoniae (1), Staphylococcus aureus (1), Histoplasma capsulatum (1), and Aspergillus fumigatus (1) .
The chest roentgenograms for all patients with respiratory Discussion tract isolates of M. xenopi revealed abnormalities. The most common radiographic changes were bilateral interstitial pulmoNontuberculous mycobacteria are frequently isolated from patients with HIV infection. In the United States, Canada, and nary infiltrates, which were evident in 14 patients. The roentgenograms for three patients demonstrated cystic changes Europe, most of these isolates are part of the M. avium complex [21, 22] , and recovery of these organisms has been associated and/or cavitation; pulmonary consolidation was also present in three patients. For five of the nine patients for whom there was with increased morbidity and mortality. M. xenopi has also been occasionally recovered from HIV-infected patients [18, no evidence of other coexisting infectious agents, the radio-
07-21-97 13:28:20 cida UC: CID The natural reservoir for M. xenopi is not known, although the organism has been recovered from water sources, including few reports of clinically significant infection due to M. xenopi in patients with AIDS [15 -18, 24] . Some of these patients seawater, hospital water taps, and hot water storage tanks [8, 25 -27] . Nosocomial infection due to M. xenopi has been rewere thought to have had pulmonary infection, and six patients with disseminated infection due to M. xenopi have been deported on the basis of the presence of the organism in hospital water systems [8] , and patients with HIV infection may be scribed previously, although few clinical details were provided [15 -18, 24] .
at greater risk of nosocomial M. xenopi infection because of recurrent and prolonged hospitalizations. It is unclear whether M. xenopi is a relatively common mycobacterial isolate in southern Ontario [6, 7] . This report describes 28 HIV-infected humans acquire the organism by ingestion or inhalation, although inhalation of contaminated aerosols is more likely bepatients in Toronto from whom M. xenopi had been isolated. Most of these patients had advanced HIV infection, low CD4 cause the organism is most often recovered from respiratory tract specimens. M. xenopi has also been recovered from a cell counts (õ100/mm 3 ), and prior AIDS-defining illnesses. The organism was most often recovered from a respiratory variety of seabirds [11] , but, to our knowledge, cases of infection associated with exposure to birds or other animals have tract specimen, although there were several extrapulmonary isolates.
not been reported. M. xenopi isolates often demonstrate reduced susceptibility It was often difficult to determine the clinical significance of the M. xenopi isolates, because the clinical and radiographic in vitro to isoniazid, rifampin, and ethambutol [3, 6, 9, 10] . However, response to therapy has been variable and has not features of M. xenopi infection are not unique and because coexistent pulmonary infection due to other pathogens was always correlated with results of in vitro susceptibility testing [8 -10] . Although treatment with standard antituberculous medcommon. Moreover, standard diagnostic criteria for nontuberculous mycobacteria infection may not be appropriate for evalications has been recommended, the optimal therapy for M. xenopi infection is uncertain. Many of the newer fluoroquiuating patients with HIV infection or AIDS. In most cases, the recovery of M. xenopi did not appear to be associated with nolones and macrolides have been found to have in vitro activity against nontuberculous mycobacteria, including M. xenopi clinical disease. However, three patients with bacteremia and disseminated disease were identified, and three other patients [28, 29] 
